HK1201858A1 - An improved process for preparation of physiologically active polypeptide complex - Google Patents
An improved process for preparation of physiologically active polypeptide complexInfo
- Publication number
- HK1201858A1 HK1201858A1 HK15102405.8A HK15102405A HK1201858A1 HK 1201858 A1 HK1201858 A1 HK 1201858A1 HK 15102405 A HK15102405 A HK 15102405A HK 1201858 A1 HK1201858 A1 HK 1201858A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- preparation
- physiologically active
- improved process
- active polypeptide
- polypeptide complex
- Prior art date
Links
- 229920001184 polypeptide Polymers 0.000 title 1
- 102000004196 processed proteins & peptides Human genes 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6883—Polymer-drug antibody conjugates, e.g. mitomycin-dextran-Ab; DNA-polylysine-antibody complex or conjugate used for therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01D—SEPARATION
- B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/10—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length using coupling agents
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Emergency Medicine (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Mycology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20120024136 | 2012-03-08 | ||
PCT/KR2013/001885 WO2013133659A1 (en) | 2012-03-08 | 2013-03-08 | An improved process for preparation of physiologically active polypeptide complex |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1201858A1 true HK1201858A1 (en) | 2015-09-11 |
Family
ID=49117067
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15102405.8A HK1201858A1 (en) | 2012-03-08 | 2015-03-10 | An improved process for preparation of physiologically active polypeptide complex |
Country Status (18)
Country | Link |
---|---|
US (1) | US11168109B2 (uk) |
EP (1) | EP2822972A4 (uk) |
JP (2) | JP6383667B2 (uk) |
KR (1) | KR101679612B1 (uk) |
CN (2) | CN110339369B (uk) |
AR (1) | AR090281A1 (uk) |
AU (1) | AU2013228144B2 (uk) |
CA (1) | CA2866473A1 (uk) |
HK (1) | HK1201858A1 (uk) |
IN (1) | IN2014DN07956A (uk) |
MX (1) | MX369613B (uk) |
MY (1) | MY165211A (uk) |
PH (1) | PH12014502004A1 (uk) |
RU (1) | RU2639256C2 (uk) |
SG (1) | SG11201405537UA (uk) |
TW (2) | TW201341395A (uk) |
UA (1) | UA114192C2 (uk) |
WO (1) | WO2013133659A1 (uk) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR081755A1 (es) * | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
CN117065044A (zh) * | 2014-03-31 | 2023-11-17 | 韩美药品株式会社 | 通过使用免疫球蛋白Fc片段连接改善蛋白质和肽的溶解度的方法 |
WO2016196017A1 (en) * | 2015-06-04 | 2016-12-08 | Antriabio, Inc. | Amine pegylation methods for the preparation of site-specific protein conjugates |
JP6987741B2 (ja) | 2015-07-24 | 2022-01-05 | ハンミ ファーマシューティカル カンパニー リミテッド | 生理活性ポリペプチド結合体の製造方法 |
CA2997263C (en) * | 2015-09-08 | 2022-10-04 | Theripion, Inc. | Apoa-1 fusion polypeptides and related compositions and methods |
WO2017052329A1 (en) * | 2015-09-24 | 2017-03-30 | Hanmi Pharm. Co., Ltd. | Protein complex by use of a specific site of an immunoglobulin fragment for linkage |
US20200283492A1 (en) * | 2017-09-29 | 2020-09-10 | Hanmi Pharm Co., Ltd. | Long acting protein complex having an enhanced efficiency |
CN111978390B (zh) * | 2020-08-31 | 2022-10-14 | 上海景泽生物技术有限公司 | 聚乙二醇修饰的rhBNP及其用途 |
Family Cites Families (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5110906A (en) | 1986-08-21 | 1992-05-05 | The Trustees Of Columbia University In The City Of New York | Derivatives of soluble T-4 |
US6096871A (en) | 1995-04-14 | 2000-08-01 | Genentech, Inc. | Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life |
ATE279947T1 (de) | 1996-03-18 | 2004-11-15 | Univ Texas | Immunglobulinähnliche domäne mit erhöhten halbwertszeiten |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6756480B2 (en) | 2000-04-27 | 2004-06-29 | Amgen Inc. | Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein |
AU9558901A (en) | 2000-10-05 | 2002-04-15 | Ares Trading Sa | Regioselective liquid phase pegylation |
KR20080085082A (ko) | 2000-12-07 | 2008-09-22 | 일라이 릴리 앤드 캄파니 | Glp-1 융합 단백질 |
US7312192B2 (en) | 2001-09-07 | 2007-12-25 | Biocon Limited | Insulin polypeptide-oligomer conjugates, proinsulin polypeptide-oligomer conjugates and methods of synthesizing same |
SE526711C2 (sv) | 2003-01-31 | 2005-10-25 | Probi Ab | Nya stammar av Bifidobacterium med förmåga att överleva i magtarmkanalen och producera glutamin in vivo, samt kompositioner och användningar därav |
US20040180054A1 (en) | 2003-03-13 | 2004-09-16 | Hanmi Pharm. Co., Ltd. | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
US20050176108A1 (en) * | 2003-03-13 | 2005-08-11 | Young-Min Kim | Physiologically active polypeptide conjugate having prolonged in vivo half-life |
EP1613272B1 (en) | 2003-04-11 | 2013-12-18 | Antriabio, Inc. | Method for preparation of site-specific protein conjugates |
US8263084B2 (en) | 2003-11-13 | 2012-09-11 | Hanmi Science Co., Ltd | Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate |
KR101135244B1 (ko) * | 2007-11-29 | 2012-04-24 | 한미사이언스 주식회사 | 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물 |
EP2239273B1 (en) | 2003-11-13 | 2013-10-09 | Hanmi Science Co., Ltd. | A pharmaceutical composition comprosing an immunoglobulin fc as a carrier |
US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
US20080207505A1 (en) | 2005-01-12 | 2008-08-28 | James Kenneth D | Bna Conjugates and Methods of Use |
TWI376234B (en) | 2005-02-01 | 2012-11-11 | Msd Oss Bv | Conjugates of a polypeptide and an oligosaccharide |
KR100754667B1 (ko) | 2005-04-08 | 2007-09-03 | 한미약품 주식회사 | 비펩타이드성 중합체로 개질된 면역글로불린 Fc 단편 및이를 포함하는 약제학적 조성물 |
GB2427360A (en) | 2005-06-22 | 2006-12-27 | Complex Biosystems Gmbh | Aliphatic prodrug linker |
PT1928910E (pt) * | 2005-08-16 | 2014-03-06 | Hanmi Science Co Ltd | Um método para produção em massa de uma região fc da imunoglobulina com deleção dos resíduos de metionina inicial |
KR100824505B1 (ko) | 2005-08-16 | 2008-04-22 | 한미약품 주식회사 | 개시 메티오닌 잔기가 제거된 면역글로불린 Fc 영역의대량 생산방법 |
US20090252703A1 (en) * | 2006-10-19 | 2009-10-08 | Gegg Jr Colin V | Use of alcohol co-solvents to improve pegylation reaction yields |
JP2008169195A (ja) | 2007-01-05 | 2008-07-24 | Hanmi Pharmaceutical Co Ltd | キャリア物質を用いたインスリン分泌ペプチド薬物結合体 |
EP3173484B1 (en) | 2007-05-30 | 2018-09-26 | Postech Academy-Industry- Foundation | Immunoglobulin fusion proteins |
JP2009019027A (ja) | 2007-07-16 | 2009-01-29 | Hanmi Pharmaceutical Co Ltd | アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体 |
WO2009020093A1 (ja) | 2007-08-09 | 2009-02-12 | Daiichi Sankyo Company, Limited | デスドメイン含有受容体発現細胞にアポトーシスを誘導するイムノリポソーム |
TWI388570B (zh) | 2008-07-23 | 2013-03-11 | Hanmi Science Co Ltd | 包含具有三個官能端的非肽醯聚合物的多肽複合物 |
CA2747490C (en) | 2008-12-19 | 2017-02-14 | Indiana University Research And Technology Corporation | Insulin analogs |
PL2408800T3 (pl) | 2009-03-20 | 2016-11-30 | Sposób wytwarzania koniugatu miejscowo-specyficznego, fizjologicznie aktywnego polipeptydu | |
WO2011011073A1 (en) | 2009-07-22 | 2011-01-27 | Ipsen Pharma S.A.S. | Site-specific pegylated or site-specific lipidated igf-1 and analogues of igf-1 |
CA2769244A1 (en) | 2009-07-27 | 2011-02-03 | Lipoxen Technologies Limited | Glycopolysialylation of non-blood coagulation proteins |
WO2011064758A2 (en) | 2009-11-30 | 2011-06-03 | Pfizer Limited | Fusion protein |
RU2012135505A (ru) | 2010-01-19 | 2014-02-27 | Ханми Сайенс Ко., Лтд. | Жидкие составы для конъюгата этитропоэтина длительного действия |
HUE034398T2 (en) | 2010-01-19 | 2018-02-28 | Hanmi Science Co Ltd | Liquid preparations for sustained G-CSF conjugate |
AR081755A1 (es) | 2010-04-02 | 2012-10-17 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de la hormona estimuladora de los foliculos donde se usa un fragmento de inmunoglobulina, metodo de preparacion y metodo para tratar a un sujeto que sufre un trastorno reproductivo |
AR081066A1 (es) | 2010-04-02 | 2012-06-06 | Hanmi Holdings Co Ltd | Conjugado de insulina donde se usa un fragmento de inmunoglobulina |
US9981017B2 (en) | 2010-04-02 | 2018-05-29 | Hanmi Science Co., Ltd. | Insulin conjugate using an immunoglobulin fragment |
AR080993A1 (es) | 2010-04-02 | 2012-05-30 | Hanmi Holdings Co Ltd | Formulacion de accion prolongada de interferon beta donde se usa un fragmento de inmunoglobulina |
KR101330868B1 (ko) | 2010-06-08 | 2013-11-18 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 인슐린 유도체 약물 결합체 |
KR101337797B1 (ko) | 2010-07-14 | 2013-12-06 | 한미사이언스 주식회사 | 지속형 인간 성장 호르몬 결합체 액상 제제 |
KR101382593B1 (ko) * | 2010-07-21 | 2014-04-10 | 한미사이언스 주식회사 | 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물 |
KR101830344B1 (ko) | 2010-10-26 | 2018-02-22 | 한미사이언스 주식회사 | 피브로넥틴 단편 및 면역글로불린 단편의 융합 단백질 및 이의 용도 |
KR101303388B1 (ko) | 2010-10-26 | 2013-09-03 | 한미사이언스 주식회사 | 지속형 인터페론 알파 결합체의 액상 제제 |
US9803210B2 (en) | 2011-02-11 | 2017-10-31 | Research Corporation Technologies, Inc. | Fusion proteins comprising immunoglobulin constant domain-derived scaffolds |
CN103502264A (zh) | 2011-04-04 | 2014-01-08 | 国立大学法人东京医科齿科大学 | Hiv立体结构识别抗体诱导肽 |
UA113626C2 (xx) * | 2011-06-02 | 2017-02-27 | Композиція для лікування діабету, що містить кон'югат інсуліну тривалої дії та кон'югат інсулінотропного пептиду тривалої дії | |
WO2012169798A2 (en) | 2011-06-10 | 2012-12-13 | Hanmi Science Co., Ltd. | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the same |
RU2607365C2 (ru) | 2011-06-17 | 2017-01-10 | Ханми Сайенс Ко., Лтд. | Конъюгат, содержащий оксинтомодулин и фрагмент иммуноглобулина, и его применение |
RU2622077C2 (ru) | 2011-09-05 | 2017-06-09 | Ханми Сайенс Ко., Лтд. | Фармацевтическая композиция для лечения рака, содержащая конъюгат интерферона-альфа |
CN103974716B (zh) | 2011-10-06 | 2016-08-24 | 韩美科学株式会社 | 凝血因子Ⅶ和Ⅶa衍生物、包括其的缀合物和复合体及其用途 |
KR20130049671A (ko) | 2011-11-04 | 2013-05-14 | 한미사이언스 주식회사 | 생리활성 폴리펩타이드 결합체 제조 방법 |
KR101895047B1 (ko) * | 2011-12-30 | 2018-09-06 | 한미사이언스 주식회사 | 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체 |
AR090281A1 (es) | 2012-03-08 | 2014-10-29 | Hanmi Science Co Ltd | Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo |
US10064951B2 (en) | 2012-03-30 | 2018-09-04 | Hanmi Science Co., Ltd. | Liquid formulation of highly concentrated long-acting human growth hormone conjugate |
CN103509118B (zh) | 2012-06-15 | 2016-03-23 | 郭怀祖 | 胰岛素-Fc融合蛋白 |
AU2013291765C1 (en) | 2012-07-19 | 2019-08-08 | Oxford Nanopore Technologies Limited | Enzyme construct |
AR091902A1 (es) | 2012-07-25 | 2015-03-11 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de un conjugado de insulina de accion prolongada |
AR094821A1 (es) | 2012-07-25 | 2015-09-02 | Hanmi Pharm Ind Co Ltd | Formulación líquida de un conjugado de péptido insulinotrópico de acción prolongada |
AR092862A1 (es) | 2012-07-25 | 2015-05-06 | Hanmi Pharm Ind Co Ltd | Formulacion liquida de insulina de accion prolongada y un peptido insulinotropico y metodo de preparacion |
US10441665B2 (en) | 2012-07-25 | 2019-10-15 | Hanmi Pharm. Co., Ltd. | Liquid formulation of long acting insulinotropic peptide conjugate |
KR101968344B1 (ko) | 2012-07-25 | 2019-04-12 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물 |
KR101993393B1 (ko) | 2012-11-06 | 2019-10-01 | 한미약품 주식회사 | 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물 |
PT2916819T (pt) | 2012-11-06 | 2019-10-28 | Hanmi Pharm Ind Co Ltd | Formulação líquida de conjugado proteico que compreende a oxintomodulina e um fragmento de imunoglobulina. |
EP2963056B1 (en) * | 2013-02-26 | 2019-11-13 | Hanmi Pharm. Co., Ltd. | Insulin analog and use thereof |
AU2014221534B2 (en) | 2013-02-26 | 2018-06-28 | Hanmi Pharm. Co., Ltd. | Site-specific insulin conjugate |
AU2014226741B2 (en) * | 2013-03-05 | 2018-10-18 | Hanmi Pharm. Co., Ltd. | Improved preparation method for high-yield production of physiologically active polypeptide conjugate |
AR096890A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugando fc de inmunoglobulina, que mantiene la afinidad de unión del fragmento fc de la inmunoglobulina a fcrn |
AR096891A1 (es) | 2013-07-12 | 2016-02-03 | Hanmi Pharm Ind Co Ltd | Conjugado de monómero polipéptido biológicamente activo y conjugado de fragmento fc de inmunoglobulina, que muestra aclaramiento mediado por receptor reducido, y el método para la preparación del mismo |
KR102276304B1 (ko) | 2013-09-27 | 2021-07-14 | 한미약품 주식회사 | 지속형 인간 성장 호르몬 제제 |
TWI684458B (zh) | 2014-05-30 | 2020-02-11 | 南韓商韓美藥品股份有限公司 | 包含胰島素及glp-1/昇糖素雙重促效劑之治療糖尿病之組成物 |
KR20150140177A (ko) | 2014-06-05 | 2015-12-15 | 한미약품 주식회사 | 단백질 및 펩타이드의 면역원성을 감소시키는 방법 |
EP3398961B1 (en) | 2015-12-31 | 2022-06-29 | Hanmi Pharm. Co., Ltd. | Triple activator activating glucagon, glp-1 and gip receptor |
UA126662C2 (uk) | 2016-06-29 | 2023-01-11 | Ханмі Фарм. Ко., Лтд. | Похідна глюкагону, її кон'югат, композиція, яка її містить, та її терапевтичне застосування |
-
2013
- 2013-03-07 AR ARP130100755A patent/AR090281A1/es unknown
- 2013-03-08 TW TW102108193A patent/TW201341395A/zh unknown
- 2013-03-08 RU RU2014138621A patent/RU2639256C2/ru active
- 2013-03-08 SG SG11201405537UA patent/SG11201405537UA/en unknown
- 2013-03-08 MY MYPI2014002586A patent/MY165211A/en unknown
- 2013-03-08 JP JP2014560857A patent/JP6383667B2/ja active Active
- 2013-03-08 IN IN7956DEN2014 patent/IN2014DN07956A/en unknown
- 2013-03-08 CN CN201910479805.1A patent/CN110339369B/zh active Active
- 2013-03-08 AU AU2013228144A patent/AU2013228144B2/en not_active Ceased
- 2013-03-08 EP EP13757904.1A patent/EP2822972A4/en active Pending
- 2013-03-08 CN CN201380023673.2A patent/CN104271604A/zh active Pending
- 2013-03-08 KR KR1020130025344A patent/KR101679612B1/ko active IP Right Grant
- 2013-03-08 CA CA2866473A patent/CA2866473A1/en not_active Abandoned
- 2013-03-08 US US14/383,334 patent/US11168109B2/en active Active
- 2013-03-08 WO PCT/KR2013/001885 patent/WO2013133659A1/en active Application Filing
- 2013-03-08 UA UAA201410250A patent/UA114192C2/uk unknown
- 2013-03-08 MX MX2014010734A patent/MX369613B/es active IP Right Grant
- 2013-03-08 TW TW109115220A patent/TW202033536A/zh unknown
-
2014
- 2014-09-08 PH PH12014502004A patent/PH12014502004A1/en unknown
-
2015
- 2015-03-10 HK HK15102405.8A patent/HK1201858A1/xx unknown
-
2018
- 2018-03-13 JP JP2018044927A patent/JP2018104465A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
RU2014138621A (ru) | 2016-04-27 |
JP6383667B2 (ja) | 2018-08-29 |
KR101679612B1 (ko) | 2016-11-25 |
CN110339369A (zh) | 2019-10-18 |
WO2013133659A1 (en) | 2013-09-12 |
TW201341395A (zh) | 2013-10-16 |
CN104271604A (zh) | 2015-01-07 |
EP2822972A4 (en) | 2015-12-16 |
TW202033536A (zh) | 2020-09-16 |
CA2866473A1 (en) | 2013-09-12 |
RU2639256C2 (ru) | 2017-12-20 |
US11168109B2 (en) | 2021-11-09 |
EP2822972A1 (en) | 2015-01-14 |
JP2015514690A (ja) | 2015-05-21 |
UA114192C2 (uk) | 2017-05-10 |
MX2014010734A (es) | 2014-12-05 |
AU2013228144A1 (en) | 2014-09-25 |
JP2018104465A (ja) | 2018-07-05 |
SG11201405537UA (en) | 2014-11-27 |
US20150299247A1 (en) | 2015-10-22 |
KR20130103447A (ko) | 2013-09-23 |
CN110339369B (zh) | 2024-01-23 |
MY165211A (en) | 2018-03-05 |
MX369613B (es) | 2019-11-14 |
AU2013228144B2 (en) | 2017-08-17 |
IN2014DN07956A (uk) | 2015-05-01 |
PH12014502004A1 (en) | 2014-11-24 |
AR090281A1 (es) | 2014-10-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20181696T1 (hr) | Postupak za pripremu dipeptidnih derivata lizin-glutaminske kiseline | |
HK1201858A1 (en) | An improved process for preparation of physiologically active polypeptide complex | |
HK1200466A1 (en) | Method for the preparation of surfactant peptides | |
ZA201403189B (en) | Method for preparing physiologically active polypeptide complex | |
LT2734536T (lt) | Estetrolio gamybos būdas | |
IL235802A0 (en) | A new process for the preparation of 2-cyclopentyl-6-methoxy-isonicotinic acid | |
HRP20181931T1 (hr) | Kontinuirani proces za pripravu (s)-2-acetiloksipropionske kiseline | |
HK1217717A1 (zh) | 高產率製備生理活性多肽複合物的改進方法 | |
IL236450A0 (en) | Process for the preparation of 5-fluoro-h1-pyrazoles | |
PL399418A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
PL399419A1 (pl) | Sposób wytwarzania 4-metoksydihydrochalkonu | |
EP2780348A4 (en) | PROCESS FOR THE PRODUCTION OF TENOFOVIR | |
IL236466A0 (en) | Pharmaceutical composition for the release of active components | |
PT2817305T (pt) | Um processo melhorado para a preparação de aprepitant | |
HK1198647A1 (en) | Method for preparation of octahydrocyclopenta[c]pyrrole -[c] | |
EP2906536A4 (en) | IMPROVED METHOD FOR PRODUCING A PERINDOPRIL INTERMEDIATE PRODUCT | |
HU229987B1 (en) | Process for the preparation of pyrimidinyl-piperazines | |
GB201215246D0 (en) | Process for preparation of blood group antigen derivatives |